Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.

Jian Li, Mark Dowling, Anthony Jeffrey, Sergio Farina, Stephen Boyle, Ross MacDonald, Shafqat Inam, Chun Kei Kris Ma, Vinay Vanguru, Nilu Perera, Hamish Scott, Michael Dickinson, John Seymour, Andrea Henden, Emily Blyth, Phoebe Joy Ho, Constantine Tam, Mary Ann Anderson, Philip Thompson

Blood (2025) 146 (Supplement 1): 2779.

https://doi.org/10.1182/blood-2025-2779

Published: 2025

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Blood (2025) 146 (Supplement 1): 226.

https://doi.org/10.1182/blood-2025-226

Published: 2025

Journal Articles

Continuous venetoclax for relapsed chronic lymphocytic leukemia (CLL) – characteristics and outcomes of long-term responders

Sean McKeague, Thomas Lew, LeiShong Lau, Philip Thompson, Ashley Whitechurch, Dennis Carney, Gemma Reynolds, Piers Blombery, John Seymour, Andrew Roberts, Mary Ann Anderson

Blood (2025) 146 (Supplement 1): 2130.

https://doi.org/10.1182/blood-2025-2130

Published: 2025

Journal Articles

A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial

John Seymour, Andrew Aw, Vincent Ribrag, Guillaume Cartron, Arnon Kater, Ki-Seong Eom, Alan Skarbnik, Alessandra Tedeschi, Malgorzata Wach, Jing-Zhou Hou, Arpad Illes, Batul Suterwala, Jiefen Munley, Ellie John, Toshifumi Fujimori, Jennifer Brown

Blood (2025) 146 (Supplement 1): 2118.

https://doi.org/10.1182/blood-2025-2118

Published: 2025

Journal Articles

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

Blood (2025) 146 (Supplement 1): 2115.

https://doi.org/10.1182/blood-2025-2115

Published: 2025

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Blood (2025) 146 (Supplement 1): 665.

https://doi.org/10.1182/blood-2025-665

Published: 2025

Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study

Romain Guieze, Annamaria Frustaci, Chan Cheah, John Seymour, Dok Hyun Yoon, Irina Mocanu, Eric Mou, Pier Luigi Zinzani, Amitkumar Mehta, Constantine Tam, Judith Trotman, Yanan Zhang, Linlin Xu, Kunthel By, Amber Lussier, Shannon Fabre, Daniel Persky, Ranjana Advani

Blood (2025) 146 (Supplement 1): 3584.

https://doi.org/10.1182/blood-2025-3584

Published: 2025

Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study

Constantine Tam, Chan Cheah, John Seymour, Ricardo Parrondo, Mazyar Shadman, Damien Roos Weil, Stephan Stilgenbauer, Barbara Eichhorst, Herbert Eradat, Steven Treon, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Motohisa Takai, Amit Agarwal, Annamaria Frustaci

Blood (2025) 146 (Supplement 1): 3583.

https://doi.org/10.1182/blood-2025-3583

Published: 2025

Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study

Blood (2025) 146 (Supplement 1): 85.

https://doi.org/10.1182/blood-2025-85

Published: 2025

Journal Articles

CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Meghan Thompson, Constantine Tam, Kenneth Wu, Sheel Patel, Motohisa Takai, Patrick Phuong, Shelonitda Rose, Mark-David Levin, Talha Munir, Paolo Ghia, John Seymour

Blood (2025) 146 (Supplement 1): 5691.

https://doi.org/10.1182/blood-2025-5691

Published: 2025

Journal Articles

Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma treated with epcoritamab in combination with rituximab plus lenalidomide (E+R2): Primary results of the EPCORE FL-1 trial

Kim Linton, Franck Morschhauser, Marcel Nijland, Huiqiang Huang, John Seymour, Catherine Thieblemont, Abualbishr Alshreef, Jennifer Lord-Bessen, Rajesh Kamalakar, Zhijie Ding, Gauri Sunkersett, Jian Mei, Lorenzo Falchi

Blood (2025) 146 (Supplement 1): 5370.

https://doi.org/10.1182/blood-2025-5370

Published: 2025

Journal Articles

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study

Meghan Thompson, Annamaria Frustaci, John Seymour, John Allan, Paolo Ghia, Olivier Dumas, Franck Morschhauser, Martin Dreyling, Stephan Stilgenbauer, Inhye Ahn, Romain Guieze, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Daniel Persky, Amit Agarwal, Carlo Visco

Blood (2025) 146 (Supplement 1): 3895.

https://doi.org/10.1182/blood-2025-3895

Published: 2025

Journal Articles

primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma

Blood (2025) 146 (Supplement 1): 466.

https://doi.org/10.1182/blood-2025-466

Published: 2025

Journal Articles

CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor

Constantine Tam, John Seymour, Jiayi Shen, Jan Michel, Maryam Sarraf Yazdy, Patrick Brown, Shelonitda Rose, Motohisa Takai, Meghan Thompson, Mark-David Levin, Talha Munir, Paolo Ghia, Jeff Sharman

Blood (2025) 146 (Supplement 1): 8245.

https://doi.org/10.1182/blood-2025-8245

Published: 2025

Journal Articles

Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma.

Franck Morschhauser, Paula Marlton, Umberto Vitolo, Ola Linden, John Seymour, Michael Crump, Bertrand Coiffier, Alessandro Pulsoni, Andrew Belch, Erika Lerch, Eva Kimby, Kristina Arnljots, Elisabeth Wassner, Myriam Mendila

Blood (2007) 110 (11): 645.

https://doi.org/10.1182/blood.V110.11.645.645

Published: 2007

Journal Articles

Phase II Study of Enzastaurin in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.

Frank Morschhausser, Martin Wolf, John Seymour, Herve Tilly, Michael Pfreundschuh, Hanneke Kluin-Nelemans, John Raemaekers, Mars B. van’t Veer, Noel Milpied, Guillaume Cartron, Antonio Pezzutto, Andrew Spencer, Christelle Darstein, Donald Thornton, Martin Dreyling, Felix Reyes

Blood (2006) 108 (11): 2450.

https://doi.org/10.1182/blood.V108.11.2450.2450

Published: 2006

Journal Articles

Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8 + T-cell function in Hodgkin lymphoma patients

Maher K. Gandhi, Eleanore Lambley, Jaikumar Duraiswamy, Ujjwal Dua, Corey Smith, Suzanne Elliott, Devinder Gill, Paula Marlton, John Seymour, Rajiv Khanna

Blood (2006) 108 (7): 2280–2289.

https://doi.org/10.1182/blood-2006-04-015164

Published: 2006

Journal Articles

Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.

Timothy P. Hughes, Susan Branford, John Reynolds, Rachel Koelmeyer, John Seymour, Kerry Taylor, Nancy Guzzo-Pernell, Robin Filshie, Chris Arthur, Anthony Schwarer, Mark Hertzberg, Michael Copeman, Kevin Lynch, Andrew Grigg

Blood (2005) 106 (11): 164.

https://doi.org/10.1182/blood.V106.11.164.164

Published: 2005

Journal Articles

Rituximab Maintenance Prolongs Response Duration after Salvage Therapy with R-FCM in Patients with Relapsed Follicular Lymphomas and Mantle Cell Lymphomas: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Wolfgang Hiddemann, PhD, Roswitha Forstpointner, PhD, Martin Dreyling, PhD, Martin Gramatzki, PhD, Hans-Peter Böck, MD, Mathias Hänel, MD, John Seymour, MD, Manfred Planker, MD, Ulrich Dührsen, PhD, Klaus Wilms, PhD, Martin Clemens, PhD, Wolf-Dieter Ludwig, MD, Hannes Wandt, MD, Rita Pasold, MD, Michael Unterhalt, MD

Blood (2005) 106 (11): 920.

https://doi.org/10.1182/blood.V106.11.920.920

Published: 2005

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Continuous venetoclax for relapsed chronic lymphocytic leukemia (CLL) – characteristics and outcomes of long-term responders

A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study

Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study

CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma treated with epcoritamab in combination with rituximab plus lenalidomide (E+R2): Primary results of the EPCORE FL-1 trial

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study

primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma

CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor

Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma.

Phase II Study of Enzastaurin in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.

Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8 + T-cell function in Hodgkin lymphoma patients

Maintenance of Imatinib Dose Intensity in the First Six Months of Therapy for Newly Diagnosed Patients with CML Is Predictive of Molecular Response, Independent of the Ability To Increase Dose at a Later Point.

Rituximab Maintenance Prolongs Response Duration after Salvage Therapy with R-FCM in Patients with Relapsed Follicular Lymphomas and Mantle Cell Lymphomas: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only